Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Strong Trading Volume – What’s Next?

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY) saw an uptick in trading volume on Wednesday. Approximately 1,102,757 shares traded hands during trading, an increase of 559% from the previous session’s volume of 167,361 shares. The stock last traded at $12.45 and had previously closed at $12.08.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating. According to MarketBeat, Fresenius SE & Co. currently has a consensus rating of “Buy”.

Fresenius SE & Co. Trading Up 2.9%

The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The business has a 50-day simple moving average of $13.09 and a two-hundred day simple moving average of $12.35. The stock has a market cap of $28.00 billion, a price-to-earnings ratio of 15.73 and a beta of 0.60.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $6.91 billion during the quarter, compared to analyst estimates of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. As a group, research analysts forecast that Fresenius SE & Co. will post 1.08 EPS for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.